![](/img/cover-not-exists.png)
Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer
Wong, W. W.L., Zargar, M., Berry, S. R., Ko, Y. J., Riesco-Martínez, M., Chan, K. K.W.Volume:
26
Language:
english
Journal:
Current Oncology
DOI:
10.3747/co.26.4843
Date:
October, 2019
File:
PDF, 1.12 MB
english, 2019